Saturday 17 October 2026
Export ADIL’s income statement to Excel — free account
Adial Pharmaceuticals, Inc.
ADIL Healthcare Biotechnology
In the quarter to June 2026, EPS fell 150.0% and free cash flow fell 263.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.49
0.35
+11.15%
Follow ADIL
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 693.75 | 837.50 | 625.00 | 1,050.00 | 125.00 | 36.00 | 19.25 | 5.50 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | 4,656.25 | 5,900.00 | 2,500.00 | 3,175.00 | 1,781.25 | 375.00 | 104.25 | 32.50 | |||||
| People | |||||||||||||||
| People | Employees | — | 3 | 6 | 4 | 9 | 21 | 4 | 7 | 7 | 6 | ||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | 0 | (1) | (12) | (9) | (11) | (20) | (11) | (7) | (13) | (8) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | 0 | (1) | (12) | (9) | (11) | (19) | (11) | (7) | (13) | (8) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (80.61) | (218.19) | (1,525.00) | (543.75) | (543.75) | (650.00) | (318.75) | (90.00) | (68.00) | (11.93) | |||||
| Cash flow | (52.77) | (95.17) | (328.74) | (401.18) | (383.58) | (402.34) | (278.95) | (119.42) | (35.66) | (9.71) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2.18) | 0.00 | 0.00 | 0.00 | 0.22 | |||||
| Free cash flow | (52.77) | (95.17) | (328.74) | (401.18) | (383.58) | (404.51) | (278.95) | (119.42) | (35.66) | (9.49) | |||||
| Book value | (19.90) | (191.85) | 584.38 | 451.94 | 200.31 | 118.11 | 81.71 | 71.64 | 20.96 | 7.89 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | (2) | (6) | (8) | (12) | (11) | (7) | (7) | (6) | ||||
| Capex | — | — | — | — | — | 0 | — | — | — | 0 | |||||
| Free cash flow | 0 | 0 | (2) | (6) | (8) | (12) | (11) | (7) | (7) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 0 | (1) | 4 | 7 | 4 | 4 | 3 | 3 | 3 | 5 | ||||
| Total debt | 0 | 1 | — | — | — | 0 | 0 | — | — | — | |||||
| Net debt | 0 | 0 | (4) | (7) | (4) | (6) | (4) | (3) | (4) | (6) | |||||
| Shareholders’ equity | 0 | (1) | 4 | 7 | 4 | 4 | 3 | 4 | 4 | 5 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (451.83) | (1,225.27) | (491.42) | (138.81) | (165.41) | (299.59) | (192.79) | (97.87) | (269.87) | (136.16) | ||||
| ROIC | 0.00 | 0.00 | (763.06) | (1,417.62) | 0.00 | 0.00 | 0.00 | (342.64) | (1,630.29) | 0.00 | |||||
| ROE | 76.32 | 206.97 | (675.52) | (148.36) | (195.80) | (518.38) | (375.32) | (139.22) | (323.80) | (170.73) | |||||
Negative figures in brackets.
Charts ten years each
Adial Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CSCIF COSCIENS Biopharma Inc. | $8.6M | 1.0× | — | +30.04% (above 0%: growing) | n/m | +113.30% (above 0%: growing) | 55.27% | 13.43% | Compare |
| IMRN IMMURON | $8.3M | — (loss-making) | — | +757.00% (above 0%: growing) | +12.00% (above 0%: growing) | +42.55% (above 0%: growing) | 72.16% | 0.00% | Compare |
| ADIL Adial Pharmaceuticals, Inc. | $8.3M | — (loss-making) | — | — | n/m | −263.66% (below 0%: shrinking) | 0.00% | 0.00% | |
| BOLT Bolt Biotherapeutics, Inc. | $8.2M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| SNTI Senti Biosciences, Inc. | $8.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $8.1M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $8.1M | — (loss-making) | — | −39.32% (below 0%: shrinking) | n/m | +46.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $8.0M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| CNSP CNS Pharmaceuticals, Inc. | $7.9M | — (loss-making) | — | — | n/m | +33.70% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $8.1M | — | — | −25.59% | — | +36.29% | 63.72% | 0.00% |
Adial Pharmaceuticals, Inc. (ADIL) key facts
- Adial Pharmaceuticals, Inc. (ADIL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ADIL traded at $3.49, a market capitalization of $8.3 million.
- Return on equity was −170.7% and debt-to-equity 0.00.